ecancermedicalscience

Research

Clinico-pathological characteristics and treatment outcomes of patients with de-novo metastatic breast cancer: study from a tertiary cancer centre in North-East India

29 Jul 2025
Manas Dubey, Partha Sarathi Roy, Ankur Bhattacharyya, Kakoli Medhi, Rajdeep Bose, Munlima Hazarika, Pompi Daimari Buragohain, Zaveri Mohinta, Anupam Sarma

Background: Due to fundamental biological differences, de-novo metastatic breast cancer (MBC) generally exhibits a more favourable prognosis compared to recurrent MBC. There is a notable absence of databases documenting de-novo MBC patients from North-East India.

Materials and methods: A retrospective analysis of 195 patients was performed from 1 January 2020 to 31 December 2022, covering a span of 3 years. Clinical, pathological and radiological data were extracted from medical records.

Results: The median age at diagnosis was 50 years. The median duration of symptoms was 5 months, with 66% of patients being postmenopausal. The predominant histological type was infiltrating ductal carcinoma. Baseline receptor status indicated that 108 patients (55.38%) were hormone receptor (HR) positive, 97 patients (49%) were positive for human epidermal growth factor receptor and 34 patients (16.4%) had triple-negative breast cancer. The most frequent sites of metastasis included bone (28.7%), lung (27%) and liver (17.4%), followed by non-regional lymph nodes (11.8%) and brain (5.6%). Among the 195 patients, 136 (70%) received treatment. Seventy-three patients (37.4%) underwent single-agent chemotherapy with taxanes, 48 patients (24.2%) received poly-chemotherapy and 12 patients (6.15%) were treated with up-front hormone therapy. Of the 110 patients who were HR positive, 57.2% received endocrine therapy (15 patients (13.6%) on tamoxifen and 48 patients (43.6%) on aromatase inhibitors). Among the 97 patients who were Her2-neu positive, 63 patients (65%) received trastuzumab-based therapy. The study reported a 3-year overall survival rate of 24%. Multivariate analysis indicated that the presence of oligo-metastasis, along with Her2-positive and HR-positive status, correlated with improved patient outcomes.

In conclusion, our findings suggest that patients with Her2-positive, HR-positive and oligometastatic disease experience significantly enhanced outcomes. Enhancing access to novel therapeutic options for our patient population is likely to result in improved prognoses.

Related Articles

Tooba Ali, Laraib Khan, Bilal Mazhar Qureshi, Asim Hafiz, Maria Tariq, Khurram Minhas, Nasir Ali, Ahmed Nadeem Abbasi
Solomon Kibudde, Awusi Kavuma, Bonny Abal, Moses Fredrick Katumba, Cissy Bangidde Namutale, Daniel Kanyike, Israel Luutu
Swasthik Upadhya, Sameer Rastogi, Adarsh Barwad, Shamim Ahmed Shamim, Dikhra Khan, Sudheer Arava, Vineeta Ojha, Akshit Kumar Ganesan Karthikeyan, Akshya Kumar Bisoi
Dandara Menezes de Araujo Oliveira, Rossana Veronica Mendonza Lopez, Lady Paola Aristizabal Arboleda, Maria Paula Curado
Aditya Dhanawat, Debdeep Samaddar, Bhagyashri Jadhav, Atul Tiwari, Kunal Jobanputra, Arnav Tongaonkar, Minit Jalan Shah, Nandini Menon, Priyamvada Maitre, Mahendra Pal, Amandeep Arora, Aparna Ringe, Archi Agrawal, Santosh Menon, Gagan Prakash, Vedang Murthy, Vanita Noronha, Kumar Prabhash, Amit Joshi